Do Healthy Adults Need a Continuous Glucose Monitor?

The pasta arrives. The sensor has already been at work for hours, sampling glucose in the interstitial fluid — not blood, never directly blood — and feeding the numbers to an algorithm that smooths them, lags them, and draws them as a clean line on a phone lying face-up beside the plate.

The line begins to climb. It keeps climbing. The phone vibrates. On the screen the trace has become a hill, and the hill has turned red, and a perfectly healthy person sits very still over lunch, reading the curve the way earlier generations read tea leaves — damage, destiny, or merely lunch.

The device is doing exactly what it was built to do: measuring interstitial glucose, repeatedly. The open question is what that measurement is worth to someone without diabetes — whether flattening every post-meal rise prevents disease, or only pathologizes normal physiology. For people with diabetes, CGMs can be transformative; for metabolically healthy adults, brief sensor use has not been shown to reduce diabetes, cardiovascular events, or mortality, and the evidence that could answer the question comes in categories — mechanism, biomarker, cohort, randomized outcome — that are related statements, not synonyms.

Where the claim comes from

CGMs transformed diabetes care by revealing time in range, hypoglycemia, and treatment response. Researchers then documented substantial glucose variability among people without diabetes and different responses to standardized meals. A useful disease-management sensor was recast as a general wellness score.

What the strongest human evidence shows

Studies in healthy adults show that CGMs can detect post-meal differences and support short-term behavior experiments. They also show discordance between interstitial sensor readings and venous plasma glucose, especially around rapid changes and exercise. Normative profiles overlap, and brief sensor use has not been proven to reduce diabetes, cardiovascular events, or mortality in metabolically healthy users.

A 2025 systematic review described promising roles in behavior change and cardiovascular prevention but emphasized heterogeneity and the lack of definitive outcome trials outside diabetes. Meal order, sleep, activity, stress, and prior meals all influence a trace. Two people can also receive meaningfully different numbers from measurement error rather than physiology alone.

It helps to imagine the literature as a ladder, although even that metaphor is slightly too neat. Mechanisms, short trials, cohorts, and clinical outcomes contribute different kinds of support. A spectacular rung does not place us on the roof marked “longer life.”

What the headline leaves out

CGM glucose is measured in interstitial fluid, not directly in blood, and algorithms smooth and lag values. A transient peak after eating is normal physiology; harm depends on magnitude, duration, frequency, overall glycemia, and metabolic context. Optimizing a graph can encourage unnecessary restriction without establishing clinical benefit.

And yes, this is where the dull words do the heroic work: confounding, reverse causation, measurement error, selection, sample size, duration. Reviews organize uncertainty; they do not abolish it.

Why the claim spreads so well

The sensor creates a compelling stream of personal data and turns every meal into an experiment. Red peaks are emotionally salient, and personalized anecdotes can feel more authoritative than population evidence. The business model also rewards repeated sensor purchases and increasingly strict food scoring.

An evidence-first way to use the information

A CGM may be useful for a defined clinical question, especially under professional guidance, but standard screening with fasting glucose, HbA1c, blood pressure, lipids, family history, and waist or weight context remains more interpretable for most healthy adults. Data should support sustainable behavior rather than fear of normal carbohydrates.

The personal calculation is less glamorous than the claim. How large is the likely benefit? What does it cost in money, attention, discomfort, risk, and opportunities not taken? Trying something gentle is not the same decision as replacing care or buying an invasive protocol.

A better question than “Does it work?” is “What, exactly, worked, for whom, at what dose, against what, for how long?” If the outcome was a surrogate, it should not be smuggled across the border as lifespan.

The verdict

CGMs are powerful medical devices and interesting research tools. For healthy adults, they can reveal patterns but have not been shown to improve long-term health outcomes, and eliminating every visible glucose rise is not an evidence-based goal.

This is not the last word; science is permitted to have later words. But changing the verdict will require powered, independent human trials with characterized interventions, meaningful outcomes, and honest accounting of harms. Educational, not medical advice.